FAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancer

Lung cancer has become one of the leading causes of cancer mortality worldwide, and non-small-cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Feng, Zhu, Lin, Meng, Qing-wei, Wang, Liyan, Chen, Xue-song, Zhao, Yan-bin, Xing, Ying, Wang, Xiao-yun, Cai, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959415/
https://www.ncbi.nlm.nih.gov/pubmed/27499634
http://dx.doi.org/10.2147/OTT.S98410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959415/
https://www.ncbi.nlm.nih.gov/pubmed/27499634
http://dx.doi.org/10.2147/OTT.S98410

Ejemplares similares